Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Top Stock Reports For Gilead, Oracle & Morgan Stanley

Published 09/11/2017, 03:36 AM
Updated 07/09/2023, 06:31 AM

Monday, September 11, 2017

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), Oracle (ORCL) and Morgan Stanley (NYSE:MS) (MS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Gilead’s shares have outperformed the Zacks Biotech industry year to date, gaining +20.7% vs. +17.1%. Gilead is all set to acquire Kite Pharma and enter the CAR T therapy space which represents immense potential at this juncture and a potential approval of lead candidate axi-cell will be a significant boost for Gilead’s prospects which have dampened of late.

The Zacks analyst emphasizes that an acquisition announcement was on the cards as Gilead had a strong cash balance and the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure made the company look for strategic alternatives. Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni.

However, the HCV franchise is under pressure because of competition and pricing issues. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU.

(You can read the full research report on Gilead here >>>).

Shares of Oracle have outperformed the Zacks Technology Sector year-to-date, gaining +35.7% vs. +19%. Oracle is benefiting from significant momentum in the SaaS and PaaS offerings. The Zacks analyst thinks the company’s growing cloud market share will continue to drive top-line growth for the foreseeable future.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The recent collaboration with Mitsubishi and addition of AI and machine learning features in Internet of Things (IoT) Cloud offerings is encouraging. NetSuite continues to expand customer base and was recently named as a leader among B2B commerce suites for midsize organizations by Forrester Wave report.

Meanwhile, estimates have been stable lately ahead of the company's Q1 earnings release. The company has mixed record of earnings surprises in recent quarters. However, higher investments on IaaS will affect gross margin expansion in the near-term.

(You can read the full research report on Oracle here >>>).

Buy-rated Morgan Stanley’s shares have outperformed the Zacks Finance sector over the last one year, gaining +39.3% versus the sector’s +18.9% increase. The performance was supported by the company’s impressive earnings surprise history. Earnings have surpassed expectations in each of the trailing four quarters.

The Zacks analyst likes the company’s efforts to offload its non-core assets to lower balance sheet risk and cost saving initiatives (Project Streamline), which will likely lead to improvement in profitability. These initiatives, along with enhanced capital deployment should boost investors’ confidence in the stock.

However, continued fall in corporate loan balances leading to decline in interest income remains a near-term concern for the company. (You can read the full research report on Morgan Stanley here >>>).

Other noteworthy reports we are featuring today include HCA Healthcare (HCA), Expedia (NASDAQ:EXPE) (EXPE) and Kroger (KR).

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

See Stocks Now>>

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

Hawaiian (HA) Aided by Unit Revenue Growth Amid High Costs

The Zacks analyst likes the company's performance with respect to unit revenues. Its history with respect to punctuality is also impressive.

SO.F.TER. & Nilit Buyouts, Cost Cuts Aid Celanese (CE)

The Zacks analyst thinks that operational cost savings through productivity actions as well as SO.F.TER. and Nilit acquisitions should help Celanese achieve its earnings growth target for 2017.

ABM Industries (ABM) Rides on Vision 2020 Initiatives in Q3

Per the Zacks analyst, ABM's comprehensive, strategic and transformative initiatives have driven improved third-quarter fiscal 2017 results.

Kroger's (KR) Customer 1st Strategy Aiding Top Line Growth

Per the Zacks analyst, Kroger's customer 1st strategy and digital endeavors will help propel top line.

Fitbit (FIT) Grapples with Competition, Weak APAC Market

Per the Zacks analyst, mounting competition from Apple (NASDAQ:AAPL) and Xiaomi in the wearables space and lackluster growth in the Asia Pacific (APAC) region will continue to dampen Fitbit's sales and income.

Acquisitions Aids HCA Healthcare (HCA), Weak Volumes Hurt

The Zacks analyst views favorably the company's emphasis on acquisitions which have led to revenue growth and enabled network expansion across several markets.

Henry Schein (NASDAQ:HSIC) Dental Grows on Buyouts amid Margin Woes

Henry Schein's dental business is riding high after receiving major boosts from strategic mergers with Sullivan Dental and Dentrix.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
New Upgrades

Higher Usage, Customer Growth Drives Pinnacle West (PNW)

The Zacks analyst believes Pinnacle West continues to benefit from economic improvement in its service territories, resulting in customer growth and improvement in demand.

Manitowoc (MTW) Poised Well on Improved Orders, Costs Cuts

Per the Zacks analyst, Manitowoc will gain from improved order activity lately seen in certain markets of North America. Consolidating manufacturing footprint and cutting costs will aid margins.

Fujifilm (FUJIY) to Grow on New Medium-Term Management Plan

The Zacks analyst thinks that the new VISION2019 management plan will boost Fujifilm's near-term profitability on increased cash flow generation and help create new high-margin businesses.

New Downgrades

Expedia (EXPE) Hurt by Sluggish Corporate Travel Business

Though Expedia's corporate travel segment continues to benefit from the acquisition of VIA Travel, the Zacks analyst expects it to remain sluggish due to cautious corporate spending.

Southern (SO) Wrecked by Vogtle, Kemper Project Overruns

The Zacks analyst believes that Southern Company (NYSE:SO) shares will decline on continued timing and cost overrun issues over two large construction projects - Vogtle and Kemper.

Cracker Barrel (CBRL) Hurt by Rising Costs, Industry Woes

Industry headwinds resulting in soft traffic trends have been hurting Cracker Barrel comps. Also, higher labor as well as costs allied to initiatives may dent margins, per the Zacks analyst.



Oracle Corporation (NYSE:ORCL

Morgan Stanley (MS): Free Stock Analysis Report

Kroger Company (The) (NYSE:KR

HCA Holdings, Inc. (HCA): Free Stock Analysis Report
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Gilead Sciences, Inc. (NASDAQ:GILD

Expedia, Inc. (EXPE): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.